In short
This article explores clinical trials investigating the use of pneumococcal polysaccharide serotype 22F conjugate vaccine, a component of the 20-valent pneumococcal conjugate vaccine (20vPnC). These trials aim to evaluate the vaccine's immune response, safety, and effectiveness in preventing pneumococcal disease in various populations. The studies focus on aspects such as vaccine-induced immunity, co-administration with other vaccines, and real-world effectiveness against community-acquired pneumonia in older adults.
At a glance
- Vaccine Composition
- 20-valent pneumococcal conjugate vaccine (20vPnC) including serotype 22F conjugated to CRM197 and adsorbed on aluminum phosphate
- Target Populations
- Adults aged 60 years and older, adults aged 65 years and older with suspected community-acquired pneumonia
- Main Objectives
- Evaluate immune response, safety, reactogenicity, and effectiveness against pneumococcal disease
- Key Endpoints
- Opsonophagocytic antibody titers, RSV neutralizing antibody titers, adverse events, vaccine effectiveness against community-acquired pneumonia
- Study Designs
- Randomized controlled trials, test-negative design for effectiveness study
- Co-administration
- Evaluation of co-administration with RSV vaccine in some trials
- Safety Assessments
- Monitoring of solicited and unsolicited adverse events, serious adverse events
- Effectiveness Measures
- Vaccine effectiveness against radiologically-confirmed community-acquired pneumonia in real-world settings
What is Pneumococcal Polysaccharide Serotype 22F Conjugated to CRM197?
Pneumococcal Polysaccharide Serotype 22F Conjugated to CRM197 Adsorbed on Aluminium Phosphate is a component of a vaccine designed to protect against pneumococcal diseases. It is part of a larger vaccine called Apexxnar, which is a 20-valent pneumococcal conjugate vaccine. This means it protects against 20 different types (serotypes) of pneumococcal bacteria, with serotype 22F being one of them.
How Does It Work?
This vaccine works by stimulating your immune system to produce antibodies against specific parts of the pneumococcal bacteria. The "22F" in the name refers to a specific serotype of pneumococcus. The vaccine contains a small piece of the outer coating (polysaccharide) of this bacteria, which is attached (conjugated) to a harmless protein called CRM197. This combination helps your immune system recognize and remember the bacteria better.
The aluminium phosphate in the vaccine acts as an adjuvant. An adjuvant is a substance that helps boost the immune response to the vaccine, making it more effective.
What Diseases Does It Treat?
This vaccine component, as part of the Apexxnar vaccine, helps prevent diseases caused by Streptococcus pneumoniae bacteria, including:
- Pneumonia: An infection of the lungs
- Bacteremia: An infection of the blood
- Meningitis: An infection of the lining of the brain and spinal cord
These diseases can be particularly serious in older adults, young children, and people with weakened immune systems.
Vaccine Composition
The Apexxnar vaccine, which includes the Pneumococcal Polysaccharide Serotype 22F component, is a suspension for injection that comes in a pre-filled syringe. It contains 20 different pneumococcal serotypes, each conjugated to CRM197 and adsorbed on aluminium phosphate.
How is the Vaccine Administered?
The vaccine is typically administered as an intramuscular injection. For adults, it's usually given as a single 0.5 ml dose. The specific vaccination schedule may vary depending on factors such as age, previous pneumococcal vaccination history, and individual risk factors. Always follow your healthcare provider's recommendations.
Effectiveness of the Vaccine
Ongoing research is being conducted to evaluate the effectiveness of the 20-valent pneumococcal conjugate vaccine (which includes the serotype 22F component) against pneumonia in adults aged 65 and older. One study aims to determine the vaccine's effectiveness against radiologically-confirmed community-acquired pneumonia (CAP) caused by vaccine serotypes.
The effectiveness is being measured by calculating the vaccine effectiveness (VE) as 1 minus the odds ratio of vaccination among cases versus controls, adjusted for potentially confounding variables.
Safety Profile
As with all vaccines, safety is a crucial aspect. The safety profile of the vaccine is being closely monitored in clinical trials. Researchers are tracking various safety indicators, including:
- The percentage of participants reporting solicited events (expected side effects) within 7 days after vaccination
- The percentage of participants reporting unsolicited adverse events within 30 days after vaccination
- The percentage of participants reporting serious adverse events up to 6 months after vaccination
It's important to note that while side effects can occur, they are generally mild and short-lived. The benefits of vaccination typically outweigh the risks for recommended individuals.
Ongoing Research
Several clinical trials are currently underway to further study this vaccine and its components:
- A study is examining the immune response to the vaccine in lymph nodes, which could provide insights into how the vaccine stimulates immunity.
- Another study is investigating the co-administration of this pneumococcal vaccine with an RSV (Respiratory Syncytial Virus) vaccine in older adults.
- A large-scale effectiveness study is being conducted to evaluate how well the vaccine prevents pneumonia in adults aged 65 and older in real-world settings.
These ongoing studies will provide more information about the vaccine's effectiveness, safety, and optimal use in different populations.